SOPHIA GENETICS SA

SOPHNASDAQ

🏆 #2518 by market capEarnings Nov 3US Equity

$7.51▼ $0.10 (−1.37%)

Live

1h▲ 0.1%

24h▼ 1.4%

7d▲ 19.2%

14d▲ 35.2%

30d▲ 31.2%

1y▲ 145.3%

🏦Market Cap

$630M

Small Cap

📈Revenue Growth (YoY)

+23.6%

Healthy

📊Gross Margin

66.6%

High

💵FCF Margin

—

⚖️P/S Ratio

7.5x

Fair

Otter Score

Weak

Trading Snapshot

Day Range: $7.45 – $7.65
52-Week Range: $2.96 – $7.88
Volume: $2.03B
Avg Volume: $1.66B
Shares Outstanding: 83.9M
Next Earnings: Oct 13, 2026

Fundamentals Snapshot

Annual Revenue: $77M
Last Q Revenue: $23M
P/E Ratio: —
P/S Ratio: 7.5x
EPS (TTM): $-1.15
Dividend Yield: —

Why Investors Own SOPH

✓High-growth profile — revenue up +25.2% YoY with expanding US Equity exposure.
✓Healthy economics — 61% gross margin and 13% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$77M▲ +29.9% YoY

Gross Margin (TTM)

60.8%▲ +4.1% YoY

Operating Income (TTM)

$10M▲ +29.9% YoY

Free Cash Flow (TTM)

$10M▲ +29.9% YoY

About SOPHIA GENETICS SA

SOPHiA GENETICS S.A. operates as a specialized company within the healthcare technology sector. The firm provides the SOPHiA DDM platform, a cloud-native Software-as-a-Service (SaaS) solution engineered to analyze diverse multimodal datasets and various diagnostic inputs, thereby extracting valuable insights. This platform, together with its related offerings and services, is widely adopted by hospitals, laboratories, and biopharmaceutical organizations across the globe. Founded in 2011, SOPHiA GENETICS S.A. is headquartered in Saint-Sulpice, Switzerland.

🦦